[
    [
        {
            "time": "2019-01-01",
            "original_text": "The best companies for employees in 2019",
            "features": {
                "keywords": [
                    "best companies",
                    "employees",
                    "2019"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "human resources",
                    "general business"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The best companies for employees in 2019",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-15",
            "original_text": "Teva stops testing its migraine drug as cluster headache treatment",
            "features": {
                "keywords": [
                    "Teva",
                    "migraine drug",
                    "cluster headache",
                    "stops testing"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Teva stops testing its migraine drug as cluster headache treatment",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",
            "features": {
                "keywords": [
                    "FDA",
                    "Alder",
                    "migraine drug",
                    "Gritstone",
                    "Lilly",
                    "Chinese sale"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "healthcare",
                    "regulatory"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-13",
            "original_text": "Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China",
            "features": {
                "keywords": [
                    "Lilly",
                    "sale",
                    "antibiotics",
                    "manufacturing facility",
                    "China"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "international business"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]